Loading
InnoCare Pharma Ltd. Stock: price and insider trades · Hong Kong
No insider purchase over the last 90 days. The latest, by Zhao Renbin, was filed 23 Jun 2026.
Insider Decl.
87
Thresholds
n/a
Buy Volume
n/a
24 ops. · all time
Sell Volume
€22M
34 ops. · all time
Who traded when
BuySaleShi Yigong4 buys3 sales
Zhao Renbin3 buys4 sales
Cui Jisong3 buys2 sales
Since the insiders bought
- +41.2%Entry HK$1.19 · Close at T+90 HK$1.68
- +41.2%Entry HK$1.19 · Close at T+90 HK$1.68
- +41.2%Entry HK$1.19 · Close at T+90 HK$1.68
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 10,306 of 26,280 companies
56.9
score / 100
Value35
Quality79
FCF yld0.1%
Earn yld3.1%
EV/EBITDA26.7x
ROE13%
Gross mgn92%
Net mgn27%
Debt/EBITDA1.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$11.80
Analyst consensus
9 analysts1.11/5
HK$8.93Target HK$19.09(+62%)HK$22.88
Income statement
RevenueHK$2.4B
Gross profitHK$2.2B92% margin
EBITDAHK$828.2M35% margin
Net incomeHK$642.5M33.0% margin
Valuation
PER (trailing)19.7x
PER (forward)65.6x
P/Book2.3x
Beta0.37
Balance sheet & cash
Market capHK$20.9B
Total debtHK$1.3B
Free Cash FlowHK$13.8M
Debt / Equity29%
Profitability & ownership
ROE12.8%
ROA4.3%
% insiders19.9%
% institutions38.5%
Last declaration on 2 October 2026
Declarations87 total
5,000,000 shares@ HK$13.8592.3% of flowShareXHKGHKEX:DA20260930E00471
5,000,000 sharesShareXHKGHKEX:DA20261001E00030
3,900,000 sharesShareXHKGHKEX:DA20260721E00042
3,900,000 sharesShareXHKGHKEX:DA20260721E00039
206,250 shares@ HK$28.300.024% mcap100.0% of flowShareXHKGHKEX:DA20260721E00034
50,000 shares@ HK$28.300.0059% mcap100.0% of flowShareXHKGHKEX:DA20260721E00043
50,000 shares@ HK$28.300.0059% mcap100.0% of flowShareXHKGHKEX:DA20260721E00040
100,000 sharesShareXHKGHKEX:DA20260715E00450
412,500 sharesShareXHKGHKEX:DA20260715E00483
100,000 sharesShareXHKGHKEX:DA20260715E00440
150,000 sharesShareXHKGHKEX:DA20260629E00167
645,000 sharesShareXHKGHKEX:DA20260629E00177
150,000 sharesShareXHKGHKEX:DA20260629E00162
412,500 sharesShareXHKGHKEX:DA20260622E00578
1,600,000 shares0ShareXHKGHKEX:DA20260622E00569
600,000 sharesShareXHKGHKEX:DA20260622E00518
Canonical exit: 17 Mar 2025 (T+90)
100,000 sharesShareXHKGHKEX:DA20260622E00566
400,000 sharesShareXHKGHKEX:DA20260622E00571
Canonical exit: 14 Sept 2023 (T+90)
400,000 sharesShareXHKGHKEX:DA20260622E00514
Canonical exit: 14 Sept 2023 (T+90)
800,000 shares0ShareXHKGHKEX:DA20260622E00517
1,600,000 shares0ShareXHKGHKEX:DA20260622E00522
1,500,000 shares0ShareXHKGHKEX:DA20260622E00520
1,650,000 sharesShareXHKGHKEX:DA20260622E00579
Canonical exit: 14 Sept 2023 (T+90)
600,000 sharesShareXHKGHKEX:DA20260622E00565
Canonical exit: 17 Mar 2025 (T+90)
2,580,000 sharesShareXHKGHKEX:DA20260622E00577
Canonical exit: 17 Mar 2025 (T+90)
25 of 87 declarations
About InnoCare Pharma Ltd.
InnoCare Pharma Ltd., a Hong Kong healthcare company worth HKD 21.8 billion, has 19.9% of its capital held by insiders and 6 filers in the record. Of 87 filings, 24 are purchases, none with an amount, and 34 are sales, only 12 of them with an amount: EUR 22.1 million in total, with a median of EUR 364,836. Purchases make up 41% of open-market trades.
The three largest sales come from two directors. Cui Jisong sold EUR 7,779,545 on September 30, 2026, and Yuan Quanhong EUR 5,319,448 on July 19, 2021 then EUR 4,699,784 on July 21, 2021. Yuan Quanhong has 11 filings of which 9 are sales and none a purchase. Zhao Renbin lodged 24 (6 purchases, 9 sales), Shi Yigong 23 (9 purchases, 6 sales) and Cui Jisong 20 (9 purchases, 6 sales), all three directors.
Read moreShow less
On June 16, 2026, three filers lodged transactions on the same day. Annual volume rises from 2 in 2025 to 37 in 2026, after 15 in 2022. The median publication delay is 1 day. Over the last twelve months: 37 filings, 10 purchases and 9 sales. The rest of the record holds 29 filings of another kind.
